Jane Street Group LLC Sells 20,543 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Jane Street Group LLC lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 33.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,265 shares of the specialty pharmaceutical company's stock after selling 20,543 shares during the period. Jane Street Group LLC owned 0.13% of Collegium Pharmaceutical worth $1,182,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in COLL. New Age Alpha Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $40,000. KBC Group NV lifted its holdings in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after acquiring an additional 982 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after buying an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after buying an additional 642 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical in the fourth quarter worth $230,000.

Insider Activity

In other news, CFO Colleen Tupper sold 977 shares of the company's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total value of $742,909.50. Following the transaction, the executive vice president now directly owns 108,137 shares in the company, valued at approximately $3,081,904.50. The trade was a 19.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock valued at $2,334,994. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Up 0.4%

NASDAQ:COLL opened at $29.96 on Wednesday. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a market cap of $962.67 million, a price-to-earnings ratio of 12.91 and a beta of 0.63. The stock has a fifty day simple moving average of $28.15 and a 200-day simple moving average of $29.80. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same period in the prior year, the firm posted $1.45 EPS. The business's revenue was up 22.7% on a year-over-year basis. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on COLL shares. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Needham & Company LLC reissued a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, StockNews.com downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $43.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.